Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 28:13:908976.
doi: 10.3389/fgene.2022.908976. eCollection 2022.

m6A Methylation in Cardiovascular Diseases: From Mechanisms to Therapeutic Potential

Longbo Li  1 , Nannan Xu  1 , Jia Liu  1 , Zhenzhen Chen  1 , Xu Liu  1 , Junnan Wang  1
Affiliations
Review

m6A Methylation in Cardiovascular Diseases: From Mechanisms to Therapeutic Potential

Longbo Li et al. Front Genet. .

Abstract

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Recent studies have shown that n6-methyladenosine (m6A) plays a major role in cardiovascular homeostasis and pathophysiology. These studies have confirmed that m6A methylation affects the pathophysiology of cardiovascular diseases by regulating cellular processes such as differentiation, proliferation, inflammation, autophagy, and apoptosis. Moreover, plenty of research has confirmed that m6A modification can delay the progression of CVD via the post-transcriptional regulation of RNA. However, there are few available summaries of m6A modification regarding CVD. In this review, we highlight advances in CVD-specific research concerning m6A modification, summarize the mechanisms underlying the involvement of m6A modification during the development of CVD, and discuss the potential of m6A modification as a therapeutic target of CVD.

Keywords: cardiovascular diseases; cardiovascular pathophysiology; epigenetics; m6A; m6A demethylase; m6A methyltransferase.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Regulation and biological function of m6A modification.
FIGURE 2
FIGURE 2
The role of m6A in CVD.
See this image and copyright information in PMC

References

    1. Alarcón C. R., Goodarzi H., Lee H., Liu X., Tavazoie S., Tavazoie S. F. (2015a). HNRNPA2B1 Is a Mediator of m6A-dependent Nuclear RNA Processing Events. Cell 162, 1299–1308. 10.1016/j.cell.2015.08.011 - DOI - PMC - PubMed
    1. Alarcón C. R., Lee H., Goodarzi H., Halberg N., Tavazoie S. F. (2015b). N6-methyladenosine Marks Primary microRNAs for Processing. Nature 519, 482–485. 10.1038/nature14281 - DOI - PMC - PubMed
    1. Andersson C., Vasan R. S. (2018). Epidemiology of Cardiovascular Disease in Young Individuals. Nat. Rev. Cardiol. 15, 230–240. 10.1038/nrcardio.2017.154 - DOI - PubMed
    1. Batista P. J., Molinie B., Wang J., Qu K., Zhang J., Li L., et al. (2014). m6A RNA Modification Controls Cell Fate Transition in Mammalian Embryonic Stem Cells. Cell Stem Cell 15, 707–719. 10.1016/j.stem.2014.09.019 - DOI - PMC - PubMed
    1. Beal P. A., Maydanovych O., Pokharel S. (2007). The Chemistry and Biology of RNA Editing by Adenosine Deaminases. Nucleic Acids Symp. Ser. 51, 83–84. 10.1093/nass/nrm042 - DOI - PubMed

LinkOut - more resources